Akso Health Group (FRA:8HX)
Germany flag Germany · Delayed Price · Currency is EUR
1.130
-0.010 (-0.88%)
At close: Jan 30, 2026

Akso Health Group Income Statement

Millions USD. Fiscal year is Apr - Mar.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '25 Mar '24 Mar '23 Mar '22 Mar '21
Operating Revenue
14.782.4113.186-
14.782.4113.186-
Revenue Growth (YoY)
512.09%-81.68%119.69%--
Cost of Revenue
15.062.2911.915.39-
Gross Profit
-0.280.121.270.61-
Selling, General & Admin
3.648.7615.542.672.03
Operating Expenses
3.648.7615.543.062.09
Operating Income
-3.92-8.64-14.27-2.46-2.09
Interest Expense
----0.8-2.15
Currency Exchange Gain (Loss)
-0-0.591.14-0.75-
Other Non Operating Income (Expenses)
0.030.140.060-0.05
EBT Excluding Unusual Items
-3.89-9.09-13.07-4.01-4.29
Impairment of Goodwill
-41.37----
Asset Writedown
-121.01----
Pretax Income
-166.27-9.09-13.07-4.01-4.29
Income Tax Expense
-30.80.020.020.09-
Earnings From Continuing Operations
-135.47-9.12-13.08-4.1-4.29
Earnings From Discontinued Operations
--0.411.84-12.75-30.53
Net Income to Company
-135.47-9.52-1.25-16.85-34.83
Minority Interest in Earnings
0.490.06-0.11-0-
Net Income
-134.98-9.46-1.36-16.85-34.83
Net Income to Common
-134.98-9.46-1.36-16.85-34.83
Shares Outstanding (Basic)
28547232016
Shares Outstanding (Diluted)
28547232016
Shares Change (YoY)
504.37%106.30%15.07%22.06%0.17%
EPS (Basic)
-0.47-0.20-0.06-0.85-2.14
EPS (Diluted)
-0.48-0.22-0.08-0.85-2.15
Free Cash Flow
1.021.35-3.25-8.6310.06
Free Cash Flow Per Share
0.000.03-0.14-0.430.62
Gross Margin
-1.91%5.06%9.63%10.09%-
Operating Margin
-26.55%-357.78%-108.23%-40.94%-
Profit Margin
-913.38%-391.77%-10.32%-280.85%-
Free Cash Flow Margin
6.92%55.97%-24.68%-143.81%-
EBITDA
-1.77--14.25-2.44-2.07
EBITDA Margin
-12.00%--108.09%-40.63%-
D&A For EBITDA
2.15-0.020.020.02
EBIT
-3.92-8.64-14.27-2.46-2.09
EBIT Margin
-26.55%--108.23%-40.94%-
Revenue as Reported
14.782.4113.186-
Advertising Expenses
-0.170.01--
Source: S&P Global Market Intelligence. Standard template. Financial Sources.